Post-Operative Pain – Pipeline Review, H2 2018
- Pages: 232
- Published: July 2018
- Report Code: GMDHC10588IDB
Global Markets Direct’s, ‘Post-Operative Pain – Pipeline Review, H2 2018’, provides an overview of the Post-Operative Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
– The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
– The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Post-Operative Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abide Therapeutics Inc
AcelRx Pharmaceuticals Inc
Adynxx Inc
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Apsen Farmaceutica SA
Cadila Healthcare Ltd
Camurus AB
Cara Therapeutics Inc
Center Laboratories Inc
CerSci Therapeutics Inc
Colby Pharmaceutical Co
Dompe Farmaceutici SpA
Eupraxia Pharmaceuticals Inc
EyeGate Pharmaceuticals Inc
Fujimoto Pharmaceutical Corp
GW Pharmaceuticals Plc
Heron Therapeutics Inc
Immupharma Plc
Innocoll AG
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Lipocure Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Medtronic Plc
Mundipharma International Ltd
Neumentum Inc
Novartis AG
Ocular Therapeutix Inc
Pacira Pharmaceuticals Inc
PainReform Ltd
Pharmaleads SA
PhytoHealth Corp
PixarBio Corp
PolyPid Ltd
RaQualia Pharma Inc
Recro Pharma Inc
Serina Therapeutics Inc
SteadyMed Therapeutics Inc
Taiwan Liposome Company Ltd
Teikoku Pharma USA Inc
Trevena Inc
Virpax Pharmaceuticals Inc
Xigen SA
YiChang Humanwell Pharmaceutical Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.